Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Wednesday, December 11, 2024 1 min read

Key Takeaway: Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Full Press Release Details

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders.

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

Biotech Analyst Ratings

M&A Tracker

News

Blogs

Modality Leaderboard

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

Full Press Release Details